TY - JOUR T1 - Clinical utility of 18F-fluorocholine positron-emission tomography/computed tomography in initial staging & recurrence evaluation and its comparison with conventional imaging in patients with prostate cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1548 LP - 1548 VL - 57 IS - supplement 2 AU - Rohit Phulsunga AU - Jaya Shukla AU - Shrawan Singh AU - Anupam Lal AU - Rajender Kumar AU - Anish Bhattacharya AU - Bhagwant Mittal Y1 - 2016/05/01 UR - http://jnm.snmjournals.org/content/57/supplement_2/1548.abstract N2 - 1548Objectives The aim of this study was to evaluate the clinical utility of 18F-fluorocholine positron emission tomography/computed tomography (18F-FCH PET/CT) in localization of primary lesion or recurrence at prostatic bed, regional and distant metastasis and its comparison with conventional imaging (MRI).Methods A total of 50 patients (mean age of 66.8, range 51 to 77) with clinical suspicion of prostatic cancer or histopathological proven cases of prostate cancer were prospectively evaluated in this study. All the patients were evaluated for primary prostatic lesion, recurrence at prostatic bed, regional and distant metastases. In all of these patients, diffusion-weighed contrast enhanced magnetic resonance imaging (DW CE-MRI) of pelvis was also done. The sensitivity, specificity, PPV and NPV of FCH PET/CT and MRI were evaluated on a per-patient basis. Histopathological examination or clinical or imaging follow-up were used as reference standard for comparison.Results FCH PET revealed true positive (TP) in 38 patients, false positive (FP) in five, true negative (TN) in six patients and false negative (FN) in one patient. Similarly MR revealed TP in 37 patients, FP in six, TN in five and FN in two patients. FCH showed sensitivity and specificity, PPV and NPV of 97.4%, 55%, 88% and 85.7% vs. 94.8 % ,46%, 84% and 71.4% for pelvic MRI respectively, for localization of primary in the prostate or recurrence at prostatic bed. The mean SUV max of the primary lesion was found to be 5.2 ± 3.6. FCH localized regional lymph nodal disease in 25 patients while CE MRI detected regional lymph nodal disease in only 17 patients. FCH localized regional skeletal lesions in 11 vs. 9 patients in MRI. For distant skeletal metastasis FCH was found to be superior to 99mTc-MDP bone scan and detected additional skeletal lesions. FCH shows lung involvement in 2 out of 50 patients and abdominal lymph nodes in 12 out of 50 patients.Conclusions Our results show that FCH PET/CT is better than MRI in localization of primary and recurrence at prostatic bed. FCH also performed better than CE-MRI for localization of regional lymph nodal disease, and had shown good correlation for detection of regional skeletal lesions. ER -